COVID-19 vaccine, its co-founder said on Saturday.China’s success in driving down COVID-19 infections has made it harder to conduct large-scale vaccine trials, and so far only a few countries have agreed to work with it.
The race for a vaccine: China leads the way in a potential coronavirus treatment “We are contacting Russia, Brazil, Chile and Saudi Arabia (for the Phase III trial), and it’s still in discussion,” Qiu Dongxu, executive director and co-founder of CanSino, told an anti-viral drug development conference in Suzhou, in eastern China.He said its Phase III trial was likely to start “pretty soon,” and the company plans to recruit 40,000 participants for the test.Its COVID-19 candidate, Ad5-nCov, became the first in China to move.